Department of Healthcare Economics

Do you have a question about reimbursement for ARALAST NP?

The Department of Healthcare Economics can help you find answers.

Baxter's Department of Healthcare Economics has expertise in assisting healthcare providers, patients, and payors with a variety of economic, insurance, and reimbursement-related issues.

Our Department of Healthcare Economics:

  • Provides coverage, support, and assistance with challenging issues
  • Coordinates patient assistance programs
  • Offers patient education programs and advocacy for insurance-related concerns
  • Facilitates gathering technical and clinical information for medical professionals
  • Analyzes and disseminates healthcare economics information to customers upon request

These services are available to Alpha-1 patients at no charge. Call the Department of Healthcare Economics (1-800-968-9937) for more information.

Do you belong to an Alpha-1 support group? Invite an HCE representative to speak at a meeting. Our HCE representatives can help your group understand the maze of insurance issues.

To request an HCE guest speaker contact us.

ARALAST NP [Alpha1-Proteinase Inhibitor (Human)]

ARALAST NP is indicated for chronic augmentation therapy in patients having congenital deficiency of A1-PI with clinically evident emphysema. ARALAST NP is not indicated as therapy for lung disease patients in whom congenital A1-PI deficiency has not been established.

The effect of augmentation therapy with ARALAST NP on pulmonary exacerbations and on the progression of emphysema in alpha1-antitrypsin deficiency has not been demonstrated in randomized, controlled clinical trials.

Please review the detailed Important Risk Information and the Full Prescribing Information

Please review the detailed Important Risk Information and the Full Prescribing Information